[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Lahey Clinic\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":116},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,73,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100647792","assessing-outcomes-of-coil-embolization-for-unilateral-vs-bilateral-chronic-subdural-hematomas-100647792",false,"NCT07715656","Assessing Outcomes of Coil Embolization for Unilateral vs Bilateral Chronic Subdural Hematomas","Assessing Outcomes of Coil Embolization for Unilateral vs Bilateral Chronic Subdural Hematomas: A Randomized Controlled Trial.","(COAST)","Inclusion Criteria:\n\nCandidates for this study must meet ALL of the following criteria:\n\n1. Subject is 18 years of age or older.\n2. Subject has a diagnosis of chronic subdural hematoma with mass effect Determined by brain imaging (CT or MRI) and correlated clinical symptoms.\n3. Pre-randomization modified Rankin Score (mRS) ≤3\n\n   a. Surgical Cohort: Assessment should reflect the subject's condition just prior to undergoing surgery. Assessment may be performed post-surgery using pre-surgical data.\n4. Subdural Hematoma Size\n\n   Medical Management Cohort:\n   * Midline shift \\\u003C 10mm and hematoma thickness \\> 10 mm as measured on coronal imaging perpendicular to the skull.\n   * No focal deficit related to the chronic subdural hematoma requiring surgical intervention\n\n   Surgical Cohort:\n\n   • No requirement\n5. A CT performed prior to randomization demonstrating stability of the hematoma. Stability is defined as no worsening of midline shift or increase in the size of the cSDH from the screening image that results in new or worsening clinical symptoms.\n6. Patient or designated Legal Authorized Representative, confirms the patient has the mental capacity, willingness and ability to comply with protocol and follow-up requirements\n7. In the opinion of the treating physician, MMA embolization is technically feasible, including evaluation of preoperative CTA, if available, or presence of a foramen spinosum bilaterally.\n\nExclusion Criteria:\n\n* Candidates will be excluded from participation if ANY of the following apply:\n\n  1. Patients presenting with an acute SDH (e.g. patient with presenting with a SDH due to trauma); mixed density is permitted.\n  2. Subject presents with bilateral cSDHs requiring treatment (contralateral cSDH \\\u003C5mm and not requiring treatment is permitted.\n  3. Subject presents with Glasgow Coma Scale \\\u003C 9\n  4. Markwalder assessment \\>4\n  5. cSDH that developed with underlying conditions such as vascular lesions, brain tumor, arachnoid cyst, spontaneous intracranial hypotension, end stage renal disease (ESRD) on hemodialysis, end stage liver disease or other comorbidities causing a coagulopathy\n  6. Prior carotid stent placement that crosses the origin of the External Carotid Artery (ECA) ipsilateral to the subdural hematoma\n  7. Presumed septic embolus, or suspicion of microbial superinfection\n  8. CT or MRI evidence of intra-cranial tumor or mass lesion\n  9. Significant contraindication to angiography (eg. kidney failure).\n  10. Life expectancy of less than 1-year\n  11. Women who are pregnant, lactating, plan on becoming pregnant during the course of the clinical investigation. We routinely do pregnancy tests prior to this procedure, to avoid radiation exposure to the fetus including radiation on follow up CT scans\n  12. Current involvement in an investigational (drug, device, etc.) clinical trial that may confound study endpoints. Subjects in observational, natural history, and\u002For epidemiological studies not involving intervention are eligible\n  13. Patient unwilling to follow SOC recommendations (e.g. refuses surgery or lifestyle modifications)","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a pragmatic, prospective, multicenter, randomized controlled trial with intention to treat analysis. In which subjects will receive either unilateral or bilateral middle meningeal artery (MMA) embolization using coils for the treatment of unilateral chronic subdural hematomas (cSDH).",[27],"Chronic Subdural Hematoma",[29,30,31,32,33],"cSDH","Chronic subdural hematoma","Coils","Embolization","eMMA","RECRUITING","2026-07-15",{"date":37,"type":38},"2026-07-20","ACTUAL",{"date":40,"type":38},"2025-04-09",{"date":42,"type":21},"2027-06-30",{"name":44,"class":45},"Lahey Clinic","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":46},"100123330","evaluation-of-non-invasive-assays-for-the-detection-of-urothelial-cancer-100123330","NCT00872495","Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer","Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer of the Bladder and Kidney","Inclusion Criteria:\n\n* Patients scheduled to have a nephroureterectomy, cystectomy, cytoscopy (newly diagnosed bladder cancer and those with recurrent disease in follow up)\n* Control Group: No known evidence of bladder cancer-one urine sample\n* \\> than 18 years of age\n\nExclusion Criteria:\n\n* \\\u003C than 18 years of age",true,{"count":56,"type":21},500,"OBSERVATIONAL","The purpose of this study is to determine if analysis of DNA and protein material found in urine will be useful in the detection of urothelial cancer of the bladder and kidney. This analysis may be helpful to determine if how a particular cancer will act regarding remission and recurrence",[60,61,62,63],"Urothelial Cancer","Cancer","Bladder Neoplasms","Urinary Bladder Cancer",[60,61,62,63],"2025-12-01",{"date":67,"type":38},"2025-12-08",{"date":69,"type":4},"2002-09",{"date":71,"type":21},"2028-11",{"name":44,"class":45},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":46},"100339184","phase-4-randomized-controlled-trial-for-ankle-fracture-pain-control-100339184","NCT03696199","Randomized Controlled Trial for Ankle Fracture Pain Control","A Prospective, Randomized Trial Evaluating Regional Anesthesia, Long-Acting Local Anesthesia, and Traditional Care for Pain Control of Operatively Treated Ankle Fractures","Inclusion Criteria:\n\n* Sustained a bimalleolar ankle fracture (OTA\u002FAO type 44 A2, B2, C1, and C2 fracture) with surgery indicated and an approach with medial and lateral incisions planned Syndesmotic injuries will be included, due to the practical difficulty of reliably determining the presence of a syndesmotic injury preoperatively Trimalleolar ankle fractures where fixation of the posterior malleolus is not planned will also be included\n* Isolated Injury\n\nExclusion Criteria:\n\n* Unifocal malleolar fractures\n* Bimalleolar fractures where fixation of only one malleolus is planned\n* Posterior malleolus fractures requiring fixation\n* Patients ineligible for a peripheral nerve block (e.g. concern for compartment syndrome)\n* Open injury\n* Patients treated with external fixation\n* Neurologic condition that would confound results (e.g. peripheral neuropathy)\n* Inability to consent\n* Chronic opioid use\n* History of opiate abuse\n* Polytrauma as defined as additional boney injury, visceral injury or moderate soft tissue injury (requiring suture repair or other invasive procedure)\n* Prisoners (unlikely to be accessible for follow-up)\n* Pregnant patients\n* Non-English-speaking subjects (post-operative data collection procedure involves conversations via phone calls. As we do not have access to translators for this research project, we will work exclusively with English-speaking subjects).\n* Subjects unable to take the standard post-operative pain regimen that consists of gabapentin, oxycodone, acetaminophen, and ibuprofen.","89 Years",{"count":82,"type":21},70,[84],"PHASE4","This project is a multicenter, three armed, prospective randomized control trial studying the effectiveness of a long-acting local anesthetic \"cocktail\" in patients undergoing operative fixation of ankle fractures.",[87],"Ankle Fractures","2025-11-03",{"date":90,"type":38},"2025-11-06",{"date":92,"type":38},"2020-09-01",{"date":94,"type":21},"2027-09-01",{"name":44,"class":45},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":46},"100607323","using-urine-tumor-dna-to-de-intensify-surveillance-in-non-muscle-invasive-bladder-cancer-100607323","NCT07187063","Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer","Inclusion Criteria:\n\n* AUA high-risk bladder cancer1\n* Received induction BCG or gemcitabine\u002Fdocetaxel\n* Negative initial post-induction therapy assessment (negative cytology and cystoscopy +\u002F- biopsy)\n\nExclusion Criteria:\n\n* High-risk NMIBC within 3 years\n* Prior induction intravesical therapy\n* Variant histology\n* Concurrent upper tract disease",{"count":103,"type":21},56,[24],"The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.",[107],"Non-muscle Invasive Bladder Cancer (NMIBC)","2025-09-18",{"date":110,"type":38},"2025-09-22",{"date":112,"type":38},"2025-01-01",{"date":114,"type":21},"2029-01-01",{"name":44,"class":45},""]